Innovative Vaccine
Technology

IVT specializes in manufacturing management, marketing, and public relations of a new generation of vaccine technologies.

IVT specializes in manufacturing management, marketing, and public relations of a new generation of vaccine technologies.


IVT is working with U.S. and global leaders in a dedicated effort to end the Covid-19 pandemic as well as assist in providing vaccines and therapeutics to combat certain cancers.


IVT identifies and partners with industry leaders in peptide production to optimize vaccine manufacturing and distribution.

About IVT

SARS-COV2

The
Hexamer Approach

Hexamer’s patented vaccine scaffold is made of non-biological peptides (strings of natural ammino acids), which should streamline FDA approval. It does not require extensive manufacturing clearance like traditional vaccines.

Compatible with
Wide Variety of Antigen

Attaching antigens using a conjugation approach is vital as the scaffold is compatible with a wide variety of antigen including non-linear elements from an
overall target (discontinuous, conformational), therefore this technology has a greater chance
of presenting native epitopes.

Critical to any antigens being tested for SARS-CoV-2 be suitability for rapid global scale manufacturing.

Scalability


ScalabilityIVT will work in partnership with global leaders in cGMP peptide manufacturing to produce billions of non-biological doses within months.
Candidate vaccines can be manufactured in as little as 7 days and are perfectly suited for validating new targets as the SARS-CoV-2 virus mutates.

Safety


The Hexamer vaccine specifically targets the virus S-Protein, is non-GMO, aluminum free and
is well tolerated and safe, thus giving piece of mind to the public. This technology is not built
on monkey adenoviruses or Virus Like Particles or GMO recombinant technologies which may
prove unsafe.

Manufacturing
Safety


The self-assembling vaccine is made from simple peptides and does not rely on chickens, bacteria or mammalian cells for production.

Efficacy
and Human Trials


Testing Hexamer's scaffold with SARS-CoV-2 targets from multiple private and government labs should result in straightforward FDA approval once efficacy is shown and will allow rapid implementation of human trials. Hexamer’s vaccine stimulates antibody production from the same areas of the corona virus upon which many monoclonal antibody therapies are based.

Logistics
and Storage


Hexamer’s vaccine can be transported and stockpiled as a dry powder without special cold-chain considerations (i.e. many mRNA vaccines need -112F storage and have a short shelf life).

Versatility


As new viral strains emerge that are resistant to current vaccines, the self-assembling vaccine can be quickly modified to target the mutated virus.

Cancer Therapies

Neoantigen Based Cancer Therapy


Hexamer’s vaccine can be transported and stockpiled as a dry powder without special cold-chain considerations (i.e. many mRNA vaccines need -112F storage and have a short shelf life).

Press Releases

View our current press release to see what the professionals are saying.

Get in Touch

Contact us at any time you have questions.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Brent Taylor | Co-Founder
Brad Call | Co-Founder
Innovative Vaccine Technologies
Email: brent@ivtglobal.com